Please enter a valid ZIP code

The safety of NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is proven

Treating a bleed Bleed
In hemophilia, a collection of blood in an area, such as a muscle or joint.
safely is important. There are many safety concerns you should be aware of. Safety should never be ignored when treating any bleeding disorder.

NovoSeven® RT has many safety features:
  • Free of human blood or plasma Plasma
    The fluid part of the blood that contains clotting factors and other proteins.
  • Risk of thrombotic Thrombotic
    Relating to or caused by thrombosis. Thrombosis is an event that takes place when veins or arteries become blocked by platelets that are working to "plug" an injury, preventing blood from flowing normally through the body, and possibly causing a stroke.
    adverse events was less than 1%*
  • Associated with a decrease in inhibitor Inhibitor
    A substance made by the body that attacks factor so it cannot work as well. For example, a Factor VIII (8) inhibitor would keep Factor VIII from working with other factors and platelets to stop bleeding.
    titers Titer
    Concentration or strength of a substance; measures the strength of an inhibitor in a person’s blood.
    in hemophilia A Hemophilia A
    A bleeding disorder caused by lack of Factor VIII (8). It is sometimes called classic or standard hemophilia.
    or B Hemophilia B
    A bleeding disorder caused by lack of Factor IX (9).
    when used as the only factor Factor
    A protein in the blood that helps form blood clots.
    agent in a study

*In patients with hemophilia A or B with inhibitors.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

Important Safety Information

WARNING: BLOOD CLOTS

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

Side Effects

Use with Other Drugs

Please click here for NovoSeven® RT Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch,
or call 1-800-FDA-1088.

NovoSeven® RT is a prescription medicine. Novo Nordisk provides patient assistance for those who qualify. Please call 1-877-NOVO-777 (1-877-668-6777) to learn more about Novo Nordisk assistance programs.